SBIR/STTR Research Award
Transmucosal oral diphenhydramine-rapid relief of nausea
Award amount
$185,654Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PINNEY ASSOCIATES
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Provided by the applicant): Development of a transmucosal oral gum
(TOG) delivery system is proposed for diphenhydramine, a first-line antiemetic
for treatment of nausea, including patients with HIV disease. Although many
antiemetics are available for use, nearly all are administered by oral
ingestion with slow onset of effects. A buffered TOG delivery system will
provide advantages over existing medications including: a) rapid delivery of
diphenhydramine into the bloodstream followed by sustained release, providing
early and lasting nausea relief; b) avoidance of first-pass effects; c)
improved bioavailability; d) user control over dosing; and e) convenience of
use. Transmucosal systems invented by this research team with demonstrated
efficacy will be adapted for diphenhydramine. Standardized, in vitro,
mechanical gum chewing methodology and a validated HPLC assay will be used in
dissolution studies to optimize performance. Gum prototypes targeted for
medication release necessary for rapid and sustained nausea relief will be
developed. Optimization of a diphenhydramine TOG delivery system will allow for
future assessment in humans and subsequent commercialization. A safe and
effective TOG medication, available over-the-counter, with a rapid onset and
sustained action will improve nausea treatment significantly.
PROPOSED COMMERCIAL APPLICATION:
The need for medication delivery systems capable of rapid relief of nausea is considerable. For people with HIV disease, nausea and vomiting are often side effects of medications or symptoms of an underlying illness. Although many antiemetics are available for use, nearly all ere administered by oral ingestion with slow onset of effects. The proposed oral transmucosal delivery of diphenhydramine by a buffered gum would provide an innovative means of rapid and sustained, safe, and effective over-the-counter treatment of nausea. A large commercial market exists for treatment of nausea in adults, especially for those suffering with HIV disease.
Technology keywords
Not reported